HomeCompareSZUKF vs MO

SZUKF vs MO: Dividend Comparison 2026

SZUKF yields 1.93% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $48.9K in total portfolio value· pulled ahead in Year 5
10 years
SZUKF
SZUKF
● Live price
1.93%
Share price
$30.30
Annual div
$0.59
5Y div CAGR
24%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.2K
Annual income
$2,432.69
Full SZUKF calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — SZUKF vs MO

📍 MO pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSZUKFMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SZUKF + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SZUKF pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SZUKF
Annual income on $10K today (after 15% tax)
$164.32/yr
After 10yr DRIP, annual income (after tax)
$2,067.79/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, MO beats the other by $23,567.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SZUKF + MO for your $10,000?

SZUKF: 50%MO: 50%
100% MO50/50100% SZUKF
Portfolio after 10yr
$55.7K
Annual income
$16,295.93/yr
Blended yield
29.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

SZUKF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
2.7
Piotroski
4/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SZUKF buys
0
MO buys
0
No recent congressional trades found for SZUKF or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSZUKFMO
Forward yield1.93%6.36%
Annual dividend / share$0.59$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR24%22.6%
Portfolio after 10y$31.2K$80.1K
Annual income after 10y$2,432.69$30,159.17
Total dividends collected$9.6K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: SZUKF vs MO ($10,000, DRIP)

YearSZUKF PortfolioSZUKF Income/yrMO PortfolioMO Income/yrGap
1$10,940$239.72$10,570$780.30+$370.00SZUKF
2$12,009$303.91$11,381$1,032.90+$628.00SZUKF
3$13,237$386.64$12,535$1,392.73+$702.00SZUKF
4$14,657$493.86$14,193$1,920.91+$464.00SZUKF
5← crossover$16,317$633.73$16,618$2,723.68$301.00MO
6$18,277$817.58$20,263$3,993.80$2.0KMO
7$20,617$1,061.28$25,936$6,098.36$5.3KMO
8$23,448$1,387.40$35,166$9,775.01$11.7KMO
9$26,918$1,828.58$51,026$16,597.78$24.1KMO
10$31,235$2,432.69$80,113$30,159.17$48.9KMO

SZUKF vs MO: Complete Analysis 2026

SZUKFStock

Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business. The Pharmaceutical Distribution Business segment procures ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers and supplies to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research and development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic products focusing on the areas of diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as improves the operations of local pharmacies and provides educational support. The Healthcare-Related Services Business segment provides manufacturer support services, such as contract distribution for manufacturers; distribution of orphan drugs; and nursing care services, as well as develops, manufactures, and sells electrocardiographs, sphygmomanometers, stethoscopes, medical materials, and health promotion equipment. Suzuken Co., Ltd. also publishes medical magazines for medical institutions. The company has collaboration with Bushu Pharmaceuticals Ltd. provide contract specialty drug services. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.

Full SZUKF Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this SZUKF vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SZUKF vs SCHDSZUKF vs JEPISZUKF vs OSZUKF vs KOSZUKF vs MAINSZUKF vs PMSZUKF vs BTISZUKF vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.